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ABBREVIATION 
ckd  - Chronic Kidney disease 
cad  - Coronary artery disease 
dm  - diabetes 
pah  - pulmonary artery hypertension 
paswp - pulmonary artery systemic hypertension 
crf  - chronic renal failure 
gfr  - glomerular Filtration Rate 
hiv  - human immune deficiency virus 
sle  - systemic lupus erythematosus 
ss  - systemic scleroses 
vsd  - ventricular septal defect 
tee  - transesophageal echo cardiography 
sht  - systemic hypertension 
copd  - chronic obstructive pulmonary disease 
ipah  - idiopathic pulmonary artery hypertension 
ild  - interstitial lung disease 
v/q  - ventilation perfusion imaging 
ecg  - Electro cardiogram 
TRV  - tricupsid Regurgitation jet velocity 
pft  - pulmonary function test 
fvc  - forced vital capacity 
fev  - forced expiratory volume 
INTRODUCTION 
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INTRODUCTION 
 
Cardiovascular disease is the leading cause of morbidity and 
mortality in dialysis patients, accounting for 50%of death
[1]
. Pulmonary 
hypertension(PHT) comprises a group of clinical and pathophysiological 
entities with similar features but a variety of underlying causes. There 
are several etiologies for PHT. Pulmonary hypertension (PHT) can be 
the result of heart, lung or systemic disorders. Regardless of the etiology, 
morbidity and mortality from long-standing PHT exceed that expected 
from the causative condition 
[2]
. 
 
PHT was frequently found in patients with chronic renal failure 
(CRF).Review of literature showed that in one study, PHT was found in 
40% of patients with end stage renal disease (ESRD) on chronic 
hemodialysis therapy via arteriovenous access
[5, 6]
. Adekunle et al. 
[7] 
stated that PHT is an independent predictor of mortality in ESRD 
patients. 
 
PHT involves vasoconstriction and obliteration of the lumen of 
small vessels in the lungs by plexiform lesions resulting in increased 
resistance to flow 
[2]
. Proposed mechanisms for the formation of the 
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plexiform lesion include dysregulation of endothelial growth and 
angiogenic response to local triggers
[3]
. Hormonal and metabolic 
derangement associated with ESRD might lead to pulmonary arterial 
vasoconstriction and an increase of the pulmonary vascular resistance
[4]
. 
 
Pulmonary artery pressure (PAP) may be further increased by high 
cardiac output resulting from the itself and also worsened by commonly 
occurring anemia and fluid overload 
[8]
. Subclinical left ventricular 
dysfunction also occurs in patients with ESRD, and is evidenced as 
abnormal myocardial diastolic rather than systolic dysfunction 
[9]
. 
 
Local vascular tone and function of pulmonary vessels re 
regulated by the balance between vasodilators, such as nitric oxide, and 
vasoconstrictors, such as thromboxane
[10]
. Patients with CRF show an 
endothelial dysfunction related to defective nitric oxide activity, which 
is not corrected by hemodialysis (HD) 
[11]
.Increased brain natriuretic 
hormone is associated with age, left ventricular hypertrophy, renal 
failure, and PHT.N-terminal pro-brain natriuretic peptide (NT-pro 
BNP)is a byproduct of brain natriuretic peptide (BNP) that has been 
shown to be of prognostic value in PHT
[15]
. 
AIM 
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AIM 
 
To study prevalence of pulmonary hypertension in chronic kidney 
disease patients. 
REVIEW OF LITERATURE 
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REVIEW OF LITERATURE 
INTRODUCTION 
Pulmonary hypertension (PHT) is characterized by elevated 
pulmonary arterial pressure and secondary right ventricular failure. It 
is a life-threatening condition with a poor prognosis if untreated. 
 
DEFINITION 
The definition of PHT is based upon right heart catheterization 
measurements. PHT is defined as a mean pulmonary artery pressure 
greater than 25 mmHg at rest 
[13]
. A mean pulmonary artery pressure of 
8 to 20 mmHg at rest is considered normal, while a mean pulmonary 
artery pressure of 21 to 24 mmHg at rest has uncertain clinical 
implications. 
 
Two definitions that were previously accepted are no longer 
used. They include a mean pulmonary artery pressure greater than 30 
mmHg with exercise (measured by right heart catheterization) 
[14] 
and a systolic pulmonary artery pressure greater than 40 mmHg 
(measured by Doppler echocardiography) 
[15]
. The latter corresponds 
to a tricuspid regurgitant velocity of 3.0 to 3.5 m/sec. 
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CLASSIFICATION 
Like its definition, the classification of PHT has changed. PHT 
was previously classified as either idiopathic pulmonary arterial 
hypertension (IPAH, formerly called primary pulmonary hypertension) 
or secondary PHT. However, it became clear that some forms of 
secondary PHT closely resemble IPAH in their histopathological 
features, natural history, and response to treatment. In an attempt to 
organize PHT on a mechanistic basis, the World Health Organization 
(WHO) classified PHT into five groups[16]. 
 
Updated clinical classification of pulmonary hypertension 
(Dana Point, 2008) 
Pulmonary arterial hypertension (PAH) 
Idiopathic PAH 
Heritable 
BMPR2 
ALK1, endoglin (with or without hereditary hemorrhagic telangiectasia) 
Unknown 
Drug- and toxin-induced 
Associated with 
Connective tissue diseases 
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HIV infection 
Portal hypertension 
Congenital heart diseases 
Schistosomiasis 
Chronic hemolytic anemia 
Persistent pulmonary hypertension of the newborn 
Pulmonary veno-occlusive disease (PVOD) and/or pulmonary capillary 
hemangiomatosis (PCH) 
 
Pulmonary hypertension owing to left heart disease 
Systolic dysfunction 
Diastolic dysfunction 
Valvular disease 
 
Pulmonary hypertension owing to lung diseases and/or hypoxia 
Chronic obstructive pulmonary disease 
Interstitial lung disease 
 
Other pulmonary diseases with mixed restrictive and obstructive pattern 
Sleep-disordered breathing 
Alveolar hypoventilation disorders 
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Chronic exposure to high altitude 
Developmental abnormalities 
 
Chronic thromboembolic pulmonary hypertension (CTEPH) 
 
Pulmonary hypertension with unclear multifactorial mechanisms 
Hematologic disorders: myeloproliferative disorders, splenectomy 
Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis: 
lymphangioleiomyomatosis, neurofibromatosis, vasculitis 
          Metabolic disorders: glycogen storage disease, Gaucher disease, 
thyroid disorders 
          Others: tumoral obstruction, fibrosingmediastinitis, chronic renal 
failure on dialysis 
ALK1: activin receptor-like kinase type 1; BMPR2: bone 
morphogenetic protein receptor type 2; HIV: human immunodeficiency 
virus. 
Reproduced from: Simonneau, G, Robbins, IM, Beghetti, M, et al. 
Updated Clinical Classifications of Pulmonary Hypertension. J Am 
CollCardiol 2009; 54:S43. Illustration used with the permission of 
Elsevier Inc. All rights reserved. 
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Group 1 PAH—―Pulmonary arterial hypertension (PAH)". 
This group consists of sporadic IPAH, heritable IPAH, and PAH 
due to diseases that localize to small pulmonary muscular arterioles. 
These include connective tissue diseases, HIV infection, portal 
hypertension, congenital heart disease, schistosomiasis, chronic 
hemolytic anemia, persistent pulmonary hypertension of the newborn, 
pulmonary veno-occlusive disease, and pulmonary capillary 
hemangiomatosis
[16]
. 
 
Drug- and toxin-induced PAH is also considered group 1 PAH. 
Exposures to the following drugs are considered definite risk factors for 
PAH: aminorex, fenfluramine, dexfenfluramine, and toxic rapeseed oil 
[16]
. In contrast, drugs that are considered likely or possible risk factors 
for PAH include amphetamines, L-tryptophan, methamphetamines, 
cocaine, phenylpropanolamine, St. John's Wort, chemotherapeutic 
agents, and selective serotonin reuptake inhibitors. 
 
The hemodynamic parameters that characterize PAH include 
the following 
[16]
: 
•Mean pulmonary artery pressure (mPAP) >25 mmHg at rest 
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•Pulmonary capillary wedge pressure (PCWP) <15 mmHg 
Supportive data include an increased pulmonary vascular 
resistance and transpulmonary gradient. The transpulmonary gradient is 
defined as the difference between the mean pulmonary artery pressure 
and the mean pulmonary capillary wedge pressure. 
Group 2 PH — "Pulmonary hypertension owing to left heart 
disease." PH due to systolic dysfunction, diastolic dysfunction, or 
valvular heart disease is included in this group 
[16]
. 
 
Group 3 PH - "Pulmonary hypertension owing to lung diseases or 
hypoxemia." 
 
This group includes PHT due to chronic obstructive pulmonary 
disease, interstitial lung disease, other pulmonary diseases with a mixed 
restrictive and obstructive pattern, sleep-disordered breathing, alveolar 
hypoventilation disorders, and other causes of hypoxemia 
[16]
. 
 
Group 4PH - "Chronic thromboembolic pulmonary hypertension." 
This group includes patients with PHt due to thromboembolic 
occlusion of the proximal or distal pulmonary vasculature 
[16]
. 
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Group 5 PH — "Pulmonary hypertension with unclear 
multifactorial mechanisms." 
 
 
These patients have PHT caused by hematologic disorders (eg, 
myeloproliferative disorders), systemic disorders (eg, sarcoidosis), 
metabolic disorders (eg, glycogen storage disease), or miscellaneous 
causes 
[16]
. 
 
In the discussion that follows, PAH is used exclusively to discuss 
group 1, whereas PH is used to discuss groups 2 through 5. In addition, 
PHt is used when referring to all groups collectively. 
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EPIDEMIOLOGY 
The prevalence of group 1 PAH in the general population is 
estimated to be 15 cases per one million adults 
[17]
. Similar estimates 
have not been performed for the five groups of PHT collectively. The 
prevalence of PHT appears to vary widely among specific populations of 
patients: 
 
 Systemic sclerosis (SSc, formerly called scleroderma) — An 
observational study of 794 patients with systemic sclerosis reported PAH 
in 12 percent of patients 
[18]
. (See "Pulmonary vascular disease in 
systemic sclerosis (scleroderma): Definition, classification, risk factors, 
screening, and prognosis".) 
 
 Portal hypertension - An observational study of 507 patients with 
portal hypertension reported PAH (ie, portopulmonary hypertension) in  
2 percent of patients 
[19]
, while a more recent study reported PAH in 
about 6 percent 
[20]
. Prevalence increases as the severity of the 
underlying cause of the portal hypertension (usually liver disease) 
worsens. (See "Portopulmonary hypertension".) 
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 Congenital heart disease - Congenital heart disease occurs in 8 out 
of every 1000 live births. Approximately 30 percent of children who do 
not have their congenital heart disease repaired will develop PAH 
[21]
. 
(See "Evaluation and prognosis of Eisenmenger syndrome", section on 
'Evaluation for congenital heart disease related pulmonary arterial 
hypertension'.) 
 
 Obstructive sleep apnea (OSA) — A review of eight studies 
estimated that the prevalence of mild PH is 15 to 20 percent among 
patients with OSA 
[22]
. (See "Cardiovascular effects of obstructive sleep 
apnea".) 
 
The only national surveillance data available was collected from 
patients with all groups of PH from 1980 to 2002 
[23]
. It is unclear how 
changes in disease recognition, reporting, and treatment during this 
period impacted the results of this study. 
 
The death rate increased from 5.2 to 5.4 per 100,000 population. 
The increase was greatest in African-Americans (4.6 to 7.3 per 100,000 
population) and women (3.3 to 5.5 per 100,000 population). The death 
rate decreased in men (8.2 to 5.4 per 100,000 population) and remained 
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stable in Caucasians (5.3 per 100,000 population). The most common 
cause of death was chronic lower respiratory disease from 1980 until 
1999. 
 
Thereafter, PHT itself was the most common cause of death. 
 
The hospitalization rate increased more than two-fold (40.8 to 90.1 
per 100,000 population). The most common cause of hospitalization from 
1980 until 1994 was chronic lower respiratory disease. Heart failure was 
the most common cause of hospitalization after 1994. 
 
ETIOLOGIES 
There are numerous causes of PAH including IPAH (both sporadic 
and hereditary), drugs and toxins, connective tissue diseases, HIV 
infection, portal hypertension, and congenital heart disease. Similarly, 
there exist many causes of PH including left heart disease, chronic 
obstructive pulmonary disease (COPD), interstitial lung disease, sleep 
related breathing disorders (eg, obstructive sleep apnea), and chronic 
thromboembolic pulmonary hypertension. A discussion of each follows. 
 
Pulmonary arterial hypertension (PAH) — The following are 
causes of group 1 PAH. 
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 Idiopathic pulmonary arterial hypertension (IPAH) — IPAH 
exists when an underlying cause of the PAH cannot be identified. It is 
usually sporadic, with only 6 to 10 percent of patients having hereditary 
disease in most series. 
 
Abnormal bone morphogenetic protein receptor type II (BMPR2) 
appears to play an important role in the pathogenesis of IPAH. In 
sporadic IPAH, up to 25 percent of patients have abnormal BMPR2 
structure or function 
[24-26]
. In hereditary IPAH, the gene that encodes 
BMPR2 (IPAH1) appears to be transmitted as an autosomal dominant 
trait with incomplete penetrance 
[19,27-31]
. In one study of 19 patients 
with hereditary IPAH, mutations likely to disrupt function of BMPR2 
were found in nine patients 
[30]
. Abnormal pulmonary vascular 
responses to exercise have been documented in asymptomatic carriers of 
IPAH1 
[32]
. 
 
Hereditary IPAH may be underdiagnosed. In one study, five 
apparently unrelated families (almost 400 individuals) were linked by 
pedigree analysis to a pair of common ancestors 
[33]
. Among these 
families, 18 individuals were found to have hereditary IPAH, determined 
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by the identification of identical BMP receptor type II mutations. Twelve 
of these subjects had been initially classified as having sporadic IPAH. 
 
 Drugs and toxins - Appetite suppressants (eg, fenfluramine, 
dexfenfluramine, and diethylpropion) increase the risk of developing 
PAH 
[24,34-37]
. In a case control study that compared 95 patients with 
PAH to 335 control patients, appetite suppressants increased the risk of 
PAH (odds ratio 6.3, 95% CI 3.0-13.2) 
[24]
. The risk was particularly 
high when the appetite suppressants were used in the preceding year or 
for more than three months. 
 
Appetite suppressant use reported by patients with all types of PHT 
is greater than that reported by the general population, suggesting that 
appetite suppressants may initiate PHT in patients with underlying 
conditions that are associated with PHT, or that obesity is associated with 
PHT
[25]
. 
 
Chronic use of cocaine or amphetamines, either inhaled or 
intravenous, has also been associated with PAH 
[28,34,38,39]
. In one 
study, cocaine or amphetamine use increased the risk of developing PAH 
approximately three times 
[34]
. PAH has also been associated with 
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recreational use of the designer amphetamine analog, 4-methyl- aminorex 
(ie, ice, euphoria, U-4-E-uh) 
[40]
, as well as methamphetamines, toxic 
rapeseed oil, and benfluorex
[41]
. 
 
 Connective tissue disease — Systemic sclerosis (SSc, also called 
scleroderma) causes PAH by obliteration of alveolar capillaries and 
narrowing of small arteries and arterioles due to pulmonary vascular 
disease and interstitial fibrosis. Isolated PAH appears to be more 
common in patients with limited SSc compared to patients with diffuse 
cutaneous SSc
[42]
. Rheumatoid arthritis and systemic lupus 
erythematosus (SLE) can also lead to fibrous obliteration of the 
pulmonary vascular bed. There is a marked female predominance and a 
frequent association with the Raynaud phenomenon in patients with SLE 
who develop PAH 
[26]
. 
 
 Human immunodeficiency virus (HIV) — PAH is a rare complication 
of HIV infection, occurring in approximately 1 out of every 200 HIV- 
infected patients (0.5 percent) 
[43-45]
. This is 6- to 12-times greater than 
the prevalence of PAH in individuals without HIV infection. The cause 
of HIV-related PAH is uncertain, but viral and host factors both likely 
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play an important role. HIV-related PAH is discussed in detail separately. 
 
 Portal hypertension — PAH associated with portal hypertension 
is referred to as portopulmonary hypertension. It is discussed in detail 
elsewhere. 
 
 Congenital heart disease — PAH due to congenital heart disease 
is due to pulmonary blood volume overload due to intracardiac shunting. 
Left to right shunts are most common, especially due to large 
(nonrestrictive) ventricular septal defects (VSD). PAH also occurs in 
patients with atrial septal defects (ASD). Noninvasive imaging — 
including transthoracic echocardiography, transesophageal 
echocardiography (TEE), and magnetic resonance imaging (MRI) — can 
be used to characterize cardiac anatomy and function in patients with 
congenital heart defects. 
 
Pulmonary hypertension (PH) — The following are causes of 
group 2, group 3, group 4, or group 5 PHT. 
 
  Left heart disease — Left atrial hypertension (ie, an elevated 
pulmonary capillary wedge pressure) requires an increased pulmonary 
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artery systolic pressure to maintain an adequate driving force across the 
pulmonary vasculature. The degree of PHT that results from any given 
level of left atrial hypertension varies greatly from individual to 
individual. This reflects the multiple impediments to normal pulmonary 
vascular flow that can exist, including reactive vasoconstriction, vascular 
remodeling, and left atrial hypertension. 
 
Causes of left atrial hypertension include left ventricular systolic or 
diastolic dysfunction, mitral and aortic valve disease, restrictive 
cardiomyopathy, constrictive pericarditis, and left atrial myxoma. 
 
Heart failure and dilated cardiomyopathy are common causes of 
PHT. As an example, in a study of 108 patients with dilated 
cardiomyopathy, 26 percent had a pulmonary artery systolic pressure 
above 40 mmHg, as determined by echocardiography 
[46]
. The PHT was 
associated with a greater likelihood of death or hospitalizations  
(89 versus 32 percent). Multiple factors contribute to cardiomyopathy- 
associated PHT including chronic pulmonary venous congestion, 
recurrent transient hypoxemia, and sleep-disordered breathing 
[47]
. 
 
The importance of mitral regurgitation as a cause of PHT was 
shown in a study of 41 patients with isolated severe mitral regurgitation 
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[48]
. PHT was identified in 76 percent of patients, of which 17 percent 
had a pulmonary artery systolic pressure greater than 70 mmHg. 
 
 Chronic Obstructive Pulmonary Disease (COPD) — PHT is a 
common complication of COPD with a significant impact on outcome 
[49-51]
. As an example, one study reported a five-year survival rate less 
than 10 percent among patients with COPD and a mean pulmonary 
arterial pressure greater than 45 mmHg, compared to a five-year survival 
rate greater than 90 percent among patients with COPD and a pulmonary 
arterial pressure less than 25 mmHg 
[51]
. The prevalence of PH in 
patients with COPD is more strongly associated with hypoxemia than 
symptoms or abnormal lung function 
[51]
. 
 
 Interstitial lung disease (ILD) — ILD-related PHT can exist when 
ILD is mild, but it is more common when hypoxemia and severe 
pulmonary dysfunction exist. ILD-related PH is reviewed separately. 
 
 Sleep related breathing disorders — Obstructive sleep apnea (OSA) 
is the sleep related breathing disorder that is most often associated with 
PHT. Untreated OSA alone is associated with mild PHT. However, it 
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may be associated with significant PHT when combined with obesity 
hypoventilation syndrome (severe obesity, diminished central respiratory 
drive, and daytime hypoxemia) or other causes of hypoxemia. These 
patients have a significant risk of mortality due to progressive PHT, 
corpulmonale, or arrhythmias, although the magnitude of the risk is 
uncertain 
[52,56]
. 
 
 Chronic thromboembolic disease — Chronic proximal PE may cause 
severe PH in a small number of patients. The emboli are often 
asymptomatic and the resting arterial oxygen level may be normal; 
however, virtually all patients demonstrate oxyhemoglobin desaturation 
with exercise 
[54,55]
. 
 
Pulmonary angiography is unnecessary if a ventilation-perfusion 
(V/Q) scan is normal because a normal V/Q scan accurately excludes 
thromboembolic disease 
[56]
. When thromboembolic disease exists, 
however, pulmonary angiography is necessary to define the extent of 
disease because perfusion scans tend to underestimate the extent of 
proximal embolization 
[57]
. 
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CLINICAL MANIFESTATIONS 
In this section, the symptoms and signs of PHT are described. 
These findings may be difficult to elucidate in patients with PHT that is 
caused by an underlying condition, because manifestations of the 
underlying disease frequently obscure those of the PHT. 
 
History 
Most patients with PHT initially experience exertional dyspnea, 
lethargy, and fatigue, which are due to an inability to increase cardiac 
output with exercise 
[58,59]
. As the PHT progresses and right ventricular 
failure develops, exertional chest pain (ie, angina), exertional syncope, 
and peripheral edema may develop. In most circumstances, angina is due 
to subendocardial hypoperfusion caused by increased right ventricular 
wall stress and myocardial oxygen demand. However, angina is 
occasionally caused by dynamic compression of the left main coronary 
artery by an enlarged pulmonary artery; this risk is greatest for patients 
with a pulmonary artery trunk at least 40 mm in diameter 
[60-62]
. 
 
Passive hepatic congestion may cause anorexia and abdominal pain 
in the right upper quadrant. Less common symptoms of PHT include 
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cough, hemoptysis, and hoarseness (ie, Ortner's syndrome) due to 
compression of the left recurrent laryngeal nerve by a dilated main 
pulmonary artery. 
 
Physical examination 
The initial physical finding of PHT is usually increased intensity of 
the pulmonic component of the second heart sound, which may even 
become palpable. The second heart sound is narrowly split or single in 
patients with PHT and preserved right ventricular function. Splitting of 
the second heart sound widens as the right ventricle fails or if right 
bundle branch block develops. 
 
Auscultation of the heart may also reveal a systolic ejection 
murmur and, in more severe disease, a diastolic pulmonic regurgitation 
murmur. The right-sided murmurs and gallops are augmented with 
inspiration. 
 
Right ventricular hypertrophy is characterized by a prominent A 
wave in the jugular venous pulse, associated with a right-sided fourth 
heart sound, and either a left parasternal heave or a downward subxiphoid 
thrust. 
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Right ventricular failure results in systemic venous hypertension.  
 
This can lead to a variety of findings such as elevated jugular 
venous pressure, a right ventricular third heart sound, and a high-pitched 
tricuspid regurgitant murmur accompanied by a prominent V wave in the 
jugular venous pulse if tricuspid regurgitation is present. In addition, 
hepatomegaly, a pulsatile liver, peripheral edema, ascites, and pleural 
effusion may exist 
[63,64]
. 
 
Some patients with PHT due to severe COPD develop edema even 
in the absence of right heart failure 
[67]
. The pathogenesis of edema in 
such patients is not well understood 
[66,67]
. It has been hypothesized 
that edema may develop in these patients due to hypercapnia or 
hypoxemia. 
 
Hypercapnia is associated with an appropriate increase in proximal 
bicarbonate reabsorption, which minimizes the fall in arterial pH. This 
increase in proximal bicarbonate transport also promotes the passive 
reabsorption of sodium chloride and water, and may contribute to edema 
formation 
[68]
. 
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DIAGNOSTIC EVALUATION 
Chest radiograph 
The classic chest radiograph shows enlargement of the central 
pulmonary arteries with attenuation of the peripheral vessels, resulting in 
oligemic lung fields. Right ventricular enlargement (diminished 
retrosternal space) and right atrial dilatation (prominent right heart 
border) may also be seen. Occasionally, the underlying cause of the PHT 
is apparent on the chest radiograph (eg, interstitial lung disease). 
 
Electrocardiography 
The electrocardiogram (ECG) may demonstrate signs of right 
ventricular hypertrophy or strain, including right axis deviation, an R 
wave/S wave ratio greater than one in lead V1, incomplete or complete 
right bundle branch block, or increased P wave amplitude in lead II (P 
pulmonale) due to right atrial enlargement . Most ECG signs are specific 
but not sensitive for the detection of right ventricular disease. ECG 
changes cannot determine disease severity or prognosis 
[82,83]
. 
 
Echocardiography 
Echocardiography is performed to estimate the pulmonary artery 
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systolic pressure and to assess right ventricular size, thickness, and 
function. In addition, echocardiography can evaluate right atrial size, left 
ventricular systolic and diastolic function, and valve function, while 
detecting pericardial effusions and intracardiac shunts 
[84,85]
. 
 
Echocardiography uses Doppler ultrasound to estimate the 
pulmonary artery systolic pressure. This technique takes advantage of the 
tricuspid regurgitation that usually exists. The maximum tricuspid 
regurgitant jet velocity is recorded and the pulmonary artery systolic 
pressure (PASP) is then calculated: 
              PASP =    (4  x  TRV squared)  +  RAP 
where TRV is the maximum tricuspid regurgitant jet velocity and 
RAP is the right atrial pressure estimated from the size and respiratory 
variation of flow in the inferior vena cava. Doppler echocardiography is 
limited when an adequate tricuspid regurgitant jet cannot be identified. 
Patients with PHT may have echocardiographic signs of right 
ventricular pressure overload, including paradoxical bulging of the 
septum into the left ventricle during systole and hypertrophy of the right 
ventricular free wall and trabeculae. As the right ventricle fails, there is 
dilation and hypokinesis, septal flattening, right atrial dilation, and 
26 
 
tricuspid regurgitation. The tricuspid regurgitation is not due to an 
intrinsic abnormality of the tricuspid valve; it is a secondary 
manifestation of dilation of the tricuspid annulus and right ventricle 
[86]
. 
Other findings associated with pulmonary hypertension are pulmonic 
insufficiency and midsystolic closure of the pulmonic valve 
[87]
. The 
echocardiographic findings of PHT are summarized in the figure. 
Based upon a Doppler echocardiographic study, it can be 
determined if PHT is likely, unlikely, or possible 
[88]
: 
 PHT is likely if the PASP is >50 and the TRV is >3.4 
 PHT is unlikely if the PASP is ≤36, the TRV is ≤2.8, and there are 
no other suggestive findings 
 PHT is possible with other combinations of findings 
Doppler echocardiography may be misleading in the assessment of 
patients with suspected pulmonary hypertension, especially when an 
inadequate tricuspid regurgitant jet is over-interpreted. This was 
illustrated by an observational study of 65 patients with various types of 
PHT
[89]
. The pulmonary arterial pressure estimated by Doppler 
echocardiography was at least 10 mmHg higher or lower than that 
obtained by right heart catheterization in 48 percent of patients and, in 
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many cases, the difference in pulmonary artery pressure determined by 
the two modalities was significantly greater than 10 mmHg. 
Overestimation and underestimation of pulmonary arterial pressure 
occurred with similar frequency, although the magnitude of the 
underestimation was greater. A major limitation of the study was that 
catheterization and Doppler echocardiography were not performed 
simultaneously. 
 
The study supports our opinion that there should be a low 
threshold to evaluate patients with suspected pulmonary hypertension via 
right heart catheterization. Despite its limitations, Doppler 
echocardiography detects 
 
PHT with greater accuracy than clinical history and physical 
examination [90,91]. 
 
Pulmonary function tests 
Pulmonary function tests (PFTs) are performed to identify and 
characterize underlying lung disease that may be contributing to PHT. An 
obstructive pattern is suggestive of COPD, while restrictive disease 
suggests interstitial lung disease, neuromuscular weakness, or chest wall 
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disease. 
It is usually severe interstitial lung disease (with lung volumes 
below 50 percent of predicted) or obstructive lung disease that produces 
PHT. In most circumstances, PHT should not be attributed to lung 
disease if the PFTs are only mildly abnormal since PH itself can cause 
PFT abnormalities. As an example, a study of 79 patients with idiopathic 
pulmonary arterial hypertension (IPAH) demonstrated that more than half 
of patients had a mild to moderate decrease of forced expiratory volume 
in one second (FEV1) or forced vital capacity (FVC) compared to age 
and sex matched controls 
[92]
. The diffusing capacity for carbon 
monoxide (DLCO) is usually decreased in PHT
[92,93]
. 
 
Overnight oximetry 
Nocturnal oxyhemoglobin desaturation can be identified by 
overnight oximetry. It is common in patients with PHT and may prompt 
supplemental oxygen therapy during sleep 
[94]
. Overnight oximetry is 
not an acceptable diagnostic test for sleep related breathing disorders, 
such as obstructive sleep apnea. 
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Polysomnography 
Polysomnography is the gold standard diagnostic test for sleep 
related breathing disorders, such as obstructive sleep apnea (OSA). It 
should be performed when the clinical suspicion for OSA is high, or the 
results of overnight oximetry are discordant with clinical expectation. 
 
V/Q scan 
Ventilation-perfusion (V/Q) scanning is used to evaluate patients 
for thromboembolic disease. A normal V/Q scan accurately excludes 
chronic thromboembolic disease with a sensitivity of 96 to 97 percent 
and a specificity of 90 to 95 percent 
[95]
. When the V/Q scan suggests 
that chronic thromboembolic disease exists, pulmonary angiography is 
necessary to confirm the positive V/Q scan and to define the extent of 
disease. V/Q scans are an important part of the diagnostic evaluation 
because PHT due to chronic thromboembolic disease is potentially 
reversible with surgery. 
 
Laboratory tests 
Blood tests performed in the diagnostic evaluation of PHT include: 
HIV serology to screen for HIV-associated PHT 
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 Liver function tests to screen for portopulmonary hypertension 
 Antinuclear antibody (ANA), rheumatoid factor (RF), and 
antineutrophil cytoplasmic antibody (ANCA) titers to screen for PHT due 
to the connective tissue diseases 
 
In the appropriate clinical setting, laboratory studies looking for 
evidence of chronic hemolytic anemia (eg, sickle cell disease) or 
schistosomiasis are appropriate. terminal pro-brain natriuretic peptide 
(NT-proBNP) is the precursor of brain natriuretic peptide (BNP). Both 
peptides are released from the myocardial tissue of the right and left 
ventricle when stretched. Increasing evidence suggests that NT-proBNP 
and BNP are helpful in diagnosing heart failure. It has been hypothesized 
that measurement of either peptide may also be helpful in the diagnosis 
of PHT, since right heart failure often complicates PHT. Preliminary data 
are promising, although accuracy diminishes if renal dysfunction exists 
[96-99]
. NT-proBNP and BNP should not be used in the routine 
diagnostic evaluation of patients with suspected PHT until their value is 
confirmed in larger prospective studies. 
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Exercise testing 
Exercise testing is most commonly performed using the six-minute 
walk test (6MWT) or cardiopulmonary exercise testing. The latter can be 
performed with gas exchange measurements, echocardiography, and/or 
right heart catheterization. Exercise testing during the diagnostic 
evaluation of PH serves several purposes: 
 Screens for alternative causes of the patient's symptoms. 
 Detects exercised-induced PHT, which may be an intermediate 
stage that exists between normal and resting PHT
[100]
. 
 Determines the patient's World Health Organization (WHO) 
functional class 
[101]
, which guides therapy. 
 Establishes a baseline from which the response to therapy can be 
measured. 
  Provides prognostic information, since a longer distance walked 
during the 6MWT is associated with longer survival 
[101]
. 
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Right heart catheterization 
Right heart catheterization is necessary to confirm the diagnosis of 
PHT and accurately determine the severity of the hemodynamic 
derangements. PHT is confirmed if the mean pulmonary artery pressure 
is greater than 25 mmHg at rest 
[101]
. 
 
Right heart catheterization is also helpful in distinguishing patients 
who have group 2 PHT (PHT due to left heart disease, such as systolic 
dysfunction, diastolic dysfunction, or valvular heart disease) 
[81]
. Such 
patients have a mean pulmonary capillary wedge pressure (PCWP) ≥15 
mmHg, as measured by right heart catheterization. However, the mean 
PCWP alone is insufficient to definitively diagnose group 2 PHT because 
it may be falsely elevated due to dilatation of the pulmonary arteries and 
incomplete "wedging" of the balloon catheter. To avoid this dilemma, 
patients with a mean PCWP ≥15 mmHg should have their left heart 
filling pressure directly assessed by measuring the left ventricular end 
diastolic pressure (LVEDP) via left heart catheterization. Failure to do so 
means that some patients may be incorrectly diagnosed as having group 2 
PHT, which has important therapeutic implications. 
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The risk of incorrectly diagnosing patients with group 2 PHT on 
the basis of a falsely elevated mean PCWP was demonstrated by a 
retrospective analysis of hemodynamic data from 3926 patients with PHT 
who underwent simultaneous right and left heart catheterization 
[102]
. 
 
Among the 3346 patients who had a mean PCWP >15 mmHg, 152 
patients (5 percent) had a normal left ventricular filling pressure, defined 
as a LVEDP ≤15 mmHg. The authors of the study focused on how 
frequently the mean PCWP was ≤15 mmHg when the LVEDP was >15 
mmHg, but it should be emphasized that the mean PCWP is virtually 
always less than the LVEDP because the latter reflects the pressure at the 
end of left atrial contraction. 
 
An additional benefit of right heart catheterization is that the 
presence and/or severity of a congenital or acquired left-to-right shunt 
can be confirmed when noninvasive studies are not definitive. 
 
NATURAL HISTORY 
The natural history of untreated IPAH is the most extensively 
studied and the focus of this section. The natural history of other types of 
34 
 
PHT is variable and depends on the severity of both the PHT and the 
underlying disease. 
 
Symptomatic patients with IPAH who do not receive treatment 
have a median survival of approximately three years. Symptomatic 
patients with PAH that is associated with another disease (eg, liver 
disease, systemic sclerosis [also called scleroderma]) generally have a 
worse prognosis than patients with IPAH. However, patients with PAH 
associated with Eisenmenger syndrome are an exception because they 
have a better prognosis than patients with IPAH 
[69-71]
. 
 
Patients with severe PAH or right heart failure die sooner, usually 
within one year without treatment. As an example, patients with IPAH 
and a mean right atrial pressure ≥20 mmHg have a median survival of 
approximately one month 
[71]
. 
 
Factors that may indicate a poor prognosis include age at 
presentation greater than 45 years, World Health Organization (WHO) 
functional class III or IV, failure to improve to a lower WHO functional 
class during treatment, pericardial effusion, large right atrial size, 
elevated right atrial pressure, septal shift during diastole, decreased 
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pulmonary arterial capacitance (ie, the stroke volume divided by the 
pulmonary arterial pulse pressure), increased N-terminal brain natriuretic 
peptide level, and perhaps hypocapnia
[72-78]
. 
 
Patients with PAH who experience cardiac arrest rarely survive. In 
a retrospective study of more than 3000 patients with PAH who required 
cardiopulmonary resuscitation (CPR), only 6 percent survived for 90 
days [79]. 
 
Chronic kidney disease: 
Chronic kidney disease is spectrum of disorder with decreased 
renal function and progressive decrease in GFR.  
 
PATHOPHYSIOLOGY 
Two mechanism involved in damage 
Mechanism related to etiology 
Hypertrophy and hyperfiltration of viable glomerulus(mediated by 
various cytokines,growth factors and vasoactive substances). 
These initial adaptation become failure due to increased glomerular 
pressure and flow leads to glomerular structural abnormalities and 
filtration abnormalities causing sclerosis of remaining nephrons. 
Intrarenal RAS responsible for this change. 
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RISK FACTORS: 
 
           1.Diabetes 
 
           2.Hypertension 
 
           3.Autoimmune disease 
 
           4.African ancestry 
 
5. Low birth weight  
 
6. Previous history of acute kidney injury  
 
7.Proteinuria  
 
8.Urinary tract abnormalities  
 
9.Abnormal urinary sediment  
 
10. Obesity  
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STAGING OF CHRONIC KIDNEY DISEASE 
 
       GFR reaches peak value at third decade after which GFR starts to 
decline and reach 70ml/min/1.73m2 at 70 years of age. 
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CLINICAL AND LABORATORY MANIFESTATIONS OF CKD 
1. Hematological anemia normocytic and normochromic mainly 
due to decreased erythropoietin  
2. Cardiac manifestation ischemic heart disease and 
hypertension and heart failure are more common in ckd   
3. GI manifestation gastritis, mucosal ulceration are more 
common  
4. Electrolyte manifestation Sodium and water retention due to 
decreased excertion of sodium. May develop hyperkalemia due 
to increased catabolism, blood transfusion, hemolysis and 
metabolic acidosis. Metabolic acidosis due to retention of 
organic acids early stage it is non anion gap metabolic acidosis 
later become anion gap acidosis as ckd worsens. 
5. Skeletal manifestations Osteitis fibrosis cystica –increased 
bone turn over Adyanamic bone disease and osteomalacia- 
decreased bone turn over Elevated PTH causes brown tumor 
cardiac fibrosis and myalgia. Calciphylaxis, nephrogenic 
fibrosing dermopathy are other manifestations. 
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PHT IN CRF 
Though PHT is a common finding in patients with ESRD, very few 
studies are available. the association between PHT and ESRD. All the 
studies show around 30-40% prevalence of PHT in patients with ESRD 
and more prevalence of PHT among those on HD than those on 
conservative management. 
Studies have been done to find the causative factors of PHT in 
ESRD. Hormonal and metabolic derangement associated with ESRD 
might lead to pulmonary arterial vasoconstriction and an increase of the 
pulmonary vascular resistance 
[4]
. 
Pulmonary artery pressure (PAP) may be further increased by high 
cardiac output resulting from the arteriovenous access itself and also 
worsened by commonly occurring anemia and fluid overload 
[8]
. 
Subclinical left ventricular dysfunction also occurs in patients with 
ESRD, and is evidenced as abnormal myocardial diastolic rather than 
systolic dysfunction [9]. 
Local vascular tone and function of pulmonary vessels are 
regulated by the balance between vasodilators, such as nitric oxide, and 
vasoconstrictors, such as thromboxane 
[10]
. Patients with CRF show an 
endothelial dysfunction related to defective nitric oxide activity, which is 
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not corrected by hemodialysis (HD) 
[11]
. Increased brain natriuretic 
hormone is associated with age, left ventricular hypertrophy, renal 
failure, and PHT. N- terminal pro-brain natriuretic peptide (NT-proBNP) 
is a byproduct of brain natriuretic peptide (BNP).   
MATERIALS AND METHODS 
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METHODOLOGY 
Study Method 
The study was conducted on patients attending the in-patient/out- 
patient department of nephrology in RGGGH hospital. All patients with a 
diagnosis of chronic kidney disease where taken up for the study after the 
application of the inclusion and exclusion criteria and after obtaining 
consent. 
The biochemical data collected were the average of the last six 
readings. ECG, CXR and echocardiography to assess PHT were done to 
those patients who were selected to be included in the study. 
 
Study Place 
The study was conducted in RGGGH Hospital, Chennai. 
 
Study Population 
Patients diagnosed with chronic kidney disease presenting to 
RGGGH hospital during a time period of 6 months were included in the 
study after the application of inclusion and exclusion criteria. 
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Study Period 
The study was conducted during the time period of 6 months . All 
patients with a diagnosis of chronic kidney disease attending the 
Nephrology department who gave consent to be included in the study 
were included during this time period. Total of 101 patients were studied. 
 
Inclusion Criteria 
CKD patients on HD or conservative management  with eGFR< 
60ml/mim/m2were selected. CKD due to all etiologies and patients of all 
age groups were selected. 
 
Exclusion Criteria 
COPD 
Parenchymal Lung Disease  
Chest Wall Disease  
Previous history of PHT Previous  
pulmonary embolism  
Smoker ( >5 pack years)  
45 
 
Collagen Vascular Disease  
LV EF <50%  
Significant mitral/aortic valve disease 
HD patients were being treated with standard bicarbonate dialysis 
for 4 hours, 3 times a week. Subjects gave their informed consent and the 
study protocol was approved by the institute’s ethical Committee on 
Human Research. 
CKD: Patients with eGFR <60 mL/min/1.73 m
2
 for more than 
3months Thorough medical history and clinical examination: A 
complete history was recorded with special emphasis to detect any 
clinical condition that predisposes to PHT, comorbidities, and history of 
renal disease (etiology of renal failure, age at onset, duration of HD 
therapy, and access location, brachial or radial). 
Chest radiography and a standard 12-lead ECG: ECG findings 
suggestive of PHT were as follows: 
 right axis deviation 
 a tall R-wave and small S-wave with a R/S ratio >1 in lead V1 
 qR complex in lead V1 
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 rSR  pattern in lead V1 
 large S-wave and small R-wave with R/S ratio <1 in lead V5 
or V6 S1, S2, S3 pattern. 
ST-T segment wave depression and inversion are often present in 
the right precordial leads. Right atrial enlargement is manifested as a tall  
 
P- wave (2.5 mm) in leads II, III, and AVF and frontal P-axis of 75°. 
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The main pulmonary artery and branch pulmonary arteries are 
more prominent and so is the right atrial contour.The striking feature in 
this chest X-ray is the remarkably prominent main pulmonary artery 
segment (MPA). 
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Laboratory investigations: The mean values from the 6 months 
preceding the echo study were presented for urea, creatinine 
,hemoglobin, calcium, phosphorus and alkaline phosphatase. 
Doppler echocardiography: Two-dimensional and M- mode 
echocardiography were performed in all patients within 4 hours 
following dialysis when the patients were at optimal dry weight 
according to hydration status, blood pressure and weight. Cardiac 
dimensions were measured according to the guidelines of the American 
Society of Echocardiography. Systolic right ventricular (or pulmonary 
artery) pressure was calculated using the modified Bernoulli equation: 
PAP = 4 X (tricuspid systolic jet) 
2 
+ 10 mm Hg (estimated right atrial 
pressure). Stroke volume estimated from the left ventricular outflow tract 
velocity time integral X diameter cardiac output was calculated by 
multiplying the stroke volume by the heart rate. PHT was defined as a 
systolic PAP > 35 mm Hg 
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Echocardiogram demonstrating dilatation of the right atrium and 
ventricles on an apical four- chamber view. The left ventricle chamber 
dimensions are normal. 
OBSERVATIONS AND RESULTS 
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OBSERVATION AND RESULTS 
 
1.Age distribution of patients studied  
 
AGE GROUP FREQUENCY PERCENT 
30-40 years 20 19.8 
41-50 years 38 37.6 
51-60 years 28 27.7 
above 70 years 15 14.9 
Total 101 100.0 
 
 
Figure - 1 
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2. Frequency of CKD among male and female patients 
                      
SEX FREQUENCY PERCENT 
MALE 70 69.3 
FEMALE 31 30.7 
Total 101 100.0 
 
 
 
Figure - 2 
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3. Frequency of DM among CKD patients 
DM FREQUENCY PERCENT 
NO 58 57.4 
YES 43 42.6 
Total 101 100.0 
 
 
Figure - 3 
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4. Frequency of SHT among CKD patients 
SHT FREQUENCY PERCENT 
NO 45 44.6 
YES 56 55.4 
Total 101 100.0 
 
 
Figure - 4 
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5. Duration of CKD among study patients  
 
CKD DURATION FREQUENCY PERCENT 
<6 MONTHS 6 5.9 
6 MONTH -1 YEAR 18 17.8 
1-3 YEARS 38 37.6 
3 - 5 YEARS 22 21.8 
ABOVE 5 YEARS 17 16.8 
Total 101 100.0 
 
Figure - 5 
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6. frequency of PHT among patients studied 
STAGE FREQUENCY PERCENT 
3.00 11 10.9 
4.00 16 15.8 
5.00 74 73.3 
Total 101 100.0 
 
Figure - 6 
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7. frequency of PHT among patients studied 
PHT FREQUENCY PERCENT 
NO 86 85.1 
YES 15 14.9 
Total 101 100.0 
 
Figure - 7 
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8.Age wise distribution of PHT 
Crosstab 
 
pht 
Total 
NO YES 
age_grou
p 
30-40 years 
Count 20 0 20 
% within 
pht 
23.3% 0.0% 19.8% 
41-50 years 
Count 32 6 38 
% within 
pht 
37.2% 40.0% 37.6% 
51-60 years 
Count 21 7 28 
% within 
pht 
24.4% 46.7% 27.7% 
above 70 
years 
Count 13 2 15 
% within 
pht 
15.1% 13.3% 14.9% 
Total 
Count 86 15 101 
% within 
pht 
100.0% 100.0% 100.0% 
Pearson Chi-Square=8.446* p=0.038 
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Figure 8 
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9. Sex distribution among patients with PHT 
Crosstab 
 
pht 
Total 
NO YES 
sex 
MALE 
Count 62 8 70 
% within 
pht 
72.1% 53.3% 69.3% 
FEMAL
E 
Count 24 7 31 
% within 
pht 
27.9% 46.7% 30.7% 
Total 
Count 86 15 101 
% within 
pht 
100.0% 100.0% 100.0% 
 
Pearson Chi-Square=2.113  p=0.146 
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10. Revalence of PHT Among Diabetic Patients 
Crosstab 
 pht Total 
NO YES 
dm 
NO 
Count 49 9 58 
% within 
pht 
57.0% 60.0% 57.4% 
YES 
Count 37 6 43 
% within 
pht 
43.0% 40.0% 42.6% 
Total 
Count 86 15 101 
% within 
pht 
100.0% 100.0% 100.0% 
Pearson Chi-Square=0.48 p=0.827 
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11.Prevalence of PHT Among Hypertensive Patients 
Crosstab 
 PHT Total 
NO YES 
sht 
NO 
Count 38 7 45 
% within 
pht 
44.2% 46.7% 44.6% 
YES 
Count 48 8 56 
% within 
pht 
55.8% 53.3% 55.4% 
Total 
Count 86 15 101 
% within 
pht 
100.0% 100.0% 100.0% 
Pearson Chi-Square=0.032 p=0.858 
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12. Prevalence of PHT Among Various Stages Of CKD 
Crosstab 
 
PHT 
Total 
NO YES 
stage_ 
3.00 
Count 11 0 11 
% within 
pht 
12.8% 0.0% 10.9% 
4.00 
Count 11 5 16 
% within 
pht 
12.8% 33.3% 15.8% 
5.00 
Count 64 10 74 
% within 
pht 
74.4% 66.7% 73.3% 
Total 
Count 86 15 101 
% within 
pht 
100.0% 100.0% 100.0% 
Pearson Chi-Square=6.377*p=0.041 
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FIGURE 9 
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13. Prevalence of PHT Among Patients Undergoing Dialysis 
 
Crosstab 
 
pht 
Total 
NO YES 
dialysis 
.00 
Count 61 7 68 
% within 
pht 
70.9% 46.7% 67.3% 
1.00 
Count 25 8 33 
% within 
pht 
29.1% 53.3% 32.7% 
Total 
Count 86 15 101 
% within 
pht 
100.0% 100.0% 100.0% 
 
Pearson Chi-Square=3.418  p=0.064 
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14. Correlation between serum creatinine, calcium, phosphorus hb, 
albumin and pulmonary hypertension among ckd patients. 
 
Group Statistics  
 pht N Mean 
Std. 
Deviation 
Std. Error 
Mean 
 
creatinine 
NO 86 4.9686 3.91063 .42169 
1.649 
YES 15 6.7800 4.00931 1.03520 
calcium 
NO 86 9.0012 .71956 .07759 
2.401* 
YES 15 8.5193 .70369 .18169 
phosphorus 
NO 86 2.6930 .64183 .06921 
2.948* 
YES 15 3.2267 .67767 .17497 
hb 
NO 86 10.6314 1.61218 .17385 
2.908* 
YES 15 9.2267 2.30108 .59414 
albumin 
NO 86 3.8105 .47577 .05130 
1.355 
YES 15 3.6267 .53648 .13852 
*p<0.05 
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FIGURE 10 
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15. Correlation between serum creatinine, calcium, phosphorus hb, 
albumin and pulmonary hypertension among various stages  
of ckd patients. 
 
N 
Me
an 
Std. 
Devia
tion 
St
d. 
Err
or 
95% 
Confiden
ce 
Interval 
for Mean 
Mini
mum 
Maxi
mum 
 
Lo
wer 
Bo
und 
Up
per 
Bo
und 
f 
value 
creatin
ine 
3 
1
1 
2.0
2 
0.51 
0.1
5 
1.6
7 
2.3
6 
1.4 3.4 
11.23
7** 
4 
1
6 
2.7
3 0.47 
0.1
2 
2.4
7 
2.9
8 2 3.8 
5 
7
4 
6.2
6 4.17 
0.4
8 
5.2
9 
7.2
3 1.4 14.8 
To
tal 
1
0
1 
5.2
4 3.96 
0.3
9 
4.4
6 
6.0
2 1.4 14.8 
Calciu
m 
3 
1
1 
9.1
0 0.55 
0.1
7 
8.7
3 
9.4
7 8 10 
 4.31
7* 
4 
1
6 
9.3
6 0.94 
0.2
4 
8.8
6 
9.8
7 8 11 
5 
7
4 
8.8
1 0.67 
0.0
8 
8.6
5 
8.9
7 6.8 10.7 
To
tal 
1
0
1 
8.9
3 0.73 
0.0
7 
8.7
8 
9.0
7 6.8 11 
phosp
horus 
3 
1
1 
2.6
0 
0.53 
0.1
6 
2.2
5 
2.9
5 
2.1 3.7 
 1.64
0 
4 
1
6 
2.5
6 
0.51 
0.1
3 
2.2
8 
2.8
3 
1.6 3.7 
5 
7
4 
2.8
4 
0.71 
0.0
8 
2.6
8 
3.0
1 
1.7 4.5 
To
tal 
1
0
1 
2.7
7 
0.67 
0.0
7 
2.6
4 
2.9
0 
1.6 4.5 
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Hb 
3 
1
1 
11.
12 
1.68 
0.5
1 
9.9
9 
12.
25 
9 14.7 
 2.55
0 
4 
1
6 
11.
05 
1.54 
0.3
8 
10.
23 
11.
87 
8.3 13.2 
5 
7
4 
10.
18 
1.82 
0.2
1 
9.7
6 
10.
60 
5 15 
To
tal 
1
0
1 
10.
42 
1.79 
0.1
8 
10.
07 
10.
78 
5 15 
albumi
n 
3 
1
1 
3.7
8 
0.49 
0.1
5 
3.4
6 
4.1
1 
2.9 4.7 
 0.07
0 
4 
1
6 
3.8
3 0.53 
0.1
3 
3.5
4 
4.1
1 2.5 4.3 
5 
7
4 
3.7
7 0.48 
0.0
6 
3.6
6 
3.8
9 2.2 5.2 
To
tal 
1
0
1 
3.7
8 0.49 
0.0
5 
3.6
9 
3.8
8 2.2 5.2 
** p<0.01 *p<0.05  
DISCUSSION 
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DISCUSSION 
           Since India is capital of diabetes chronic kidney disease is also in 
increasing trend. Ckd have elevated risk of cardiac disease and other 
complications. cardiac disease is important cause of mortality in ckd 
patients.  
         Pht occurs more commonly due to increased cardiac output and in 
pulmonary blood flow. Ckd patients also have risk of developing 
pulmonary hypertension due to metabolic and hormonal abnormalities. 
This leads to increased pulmonary artery constriction and associated 
increase in pulmonary resistance. 
         Presence of AV Fistula, decreased hemoglobulin, volume overload 
status leads to increase in cardiac output and increase in pulmonary artery 
pressure. 
         Hence aim of our study is to evaluate prevalence of pulmonary 
hypertension in various stages of ckd patients and also to correlate 
presence of various clinical metabolic and hormonal parameters and its 
association in presence of pulmonary hypertension. 
 
1. Prevalence 
Pulmonary hypertension occurs more commonly due to increased 
cardiac output and increase in pulmonary blood flow. Among 101 CKD 
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patients evaluated in our study 15 patients had pulmonary hypertension 
as assessed by 2D ECHO .14.9% of CKD patient in our study group had 
pulmonary hypertension. 
 
2. Age distribution 
Age distribution of CKD patients in our study group is as follows 
            30-40 years     -  20%  -0 % 
            41- 50 years     -38%   -40% 
            51-60 years     - 28%   -46.7% 
              >60 years      -  15%  -13.3 % 
     Almost 86% of pulmonary hypertension is seen in age group 
between 41 -60 years of age group higher prevalence in this age 
group. highest prevalence 46.7% seen in 51-60 years age group this 
has significant correlation in my study group. It may also be due to 
increased duration of CKD in these patients and also presence of other 
comorbid conditions. 
 
3. Sex distribution: 
            Among 101 CKD patients studied 70 were males and 31 
were females this is due to increased male patient being admitted 
in our hospital there is no significant difference in prevalence of 
pulmonary hypertension in gender(p=0.146). 
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4. Duration of CKD: 
            Most of patients in our study group are known CKD for 
duration of 1-5 years. 38% patients between 1-3 years and 22% 
between 3-5 % years. 
 
5. Diabetes  :            
           Since India is capital of diabetes. CKD is also increase in trend. 
Almost 42 % of our patients are diabetic and there is no significant 
increase in prevalence of pulmonary hypertension among diabetes 
patients(P=0.827). 
 
6. Hypertension: 
            Almost 44% of ckd patients taken in our study group are 
hypertensive  and there is no significant increase in prevalence of 
pulmonary hypertension among hypertensive patients(P=0.858). 
 
7. Stages of CKD: 
            Stage 3  - 10% 
            Stage 4  -15% 
            Stage 5 -  73% 
            There is significant increase in prevalence of pulmonary 
hypertension  among stage 5 CKD patients. this significant 
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increase may be contributed to the presence of AV Fistula , LV 
volume overload which can lead to increase in cardiac output and 
increase in pulmonary  artery pressure 
 
8. Dialysis: 
      Among 33 patients on dialysis 8 patients had pulmonary 
hypertension which is much significant compared to non dialysis 
patient most of the patients had hemodialysis in our study group.  
Because of presence of AV fistula they had increase in 
cardiac output and increase in pulmonary artery blood flow, this 
may be the reason for increased prevalence of pulmonary 
hypertension in dialysis patient. 
 
9. Serum creatinine: 
Mean value serum creatinine among patients with 
pulmonary hypertension is 6.78. and CKD patients without 
pulmonary hypertension is 4.97 There is no significant correlation 
with level of serum creatinine and presence of pulmonary 
hypertension in our study group. 
 
10. Serum calcium  
        Mean value serum calcium among patients with pulmonary 
hypertension is 8.52 and CKD patients without pulmonary 
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hypertension is 9.0. 
There is Positive correlation between serum calcium and 
pulmonary hypertension seen. 
 
11. Serum phosphorous 
          Mean value serum phosphorous among patients with pulmonary 
hypertension is 3.23 and CKD patients without pulmonary 
hypertension is 2.69.  
      There is Positive correlation between serum phosphorus and 
pulmonary hypertension seen. 
 
12. serum hemoglobin: 
      Mean value of hemoglobin among patients with pulmonary 
hypertension is 9.23 and CKD patients without pulmonary 
hypertension is 10.63.  
        There is positive correlation seen as decrease in hemoglobin 
seen in patients with pulmonary hypertension, this may be due to 
anemia related increase in cardiac output and increase in pulmonary 
blood flow. 
 
13.S.albumin: 
     There is no significant correlation between serum albumin and 
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presence of pulmonary hypertension. Correlation between 
s.creatinine, s.calcium, s.phosphorus, hemoglobin, s.albumin among 
various stages of ckd.  
        As the stage of CKD worsens increase in s.creatinine 
(p=0.001) and decrease in s.calcium (p=0.5) had significant 
correlation with prevalence of pulmonary hypertension. there is no 
significant correlation between s.phosphorus, hemoglobin and 
s.albumin with PHT. 
  
CONCLUSION 
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CONCLUSION 
 
1. There is increased prevalence of pulmonary hypertension seen in 
CKD patients in this study group.      
 
2. Prevalence of pulmonary hypertension is high among stage 5 CKD 
patients and its also increased in patients on dialysis. 
 
3. There is no gender predisposition for development of pulmonary 
hypertension in CKD patients . 
 
4. Development of pulmonary hypertension is not related to  diabetes 
and hypertension. 
 
5. There is positive correlation between lower hemoglobin , lower 
serum calcium and high phosphorus value in CKD patients with 
pulmonary hypertension. 
 
6. Assessment of volume overload status and correction of anemia 
may be helpful 
 
7. Duration of dialysis is associated with increased prevalence of 
pulmonary hypertension hence renal transplant may be helpful 
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8. Pulmonary hypertension is one of the complication in ckd patients  
which occurs mainly due to metabolic and hormonal 
derrangements presence of pulmonary hypertension may be 
responsible for  increased cardiovascular risk. hence measure 
should be taken to reduce prevalence of pulmonary hypertension in 
ckd patients    
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